Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11944627

    Methods for treating hematological malignancies and Ewing's sarcoma

    Kura Oncology, Inc. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11946049

    tRNA/pre-miRNA compositions and use in treating cancer

    The Regents of the University of California · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11938124

    Combination therapy for treatment of cancer

    PMV PHARMACEUTICALS, INC. · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11939596

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11932606

    Anti-cancer/anti-fibrosis compounds

    The Regents of the University of California · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11932692

    Methods of treating cancer pain by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11926668

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11925629

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11925663

    Methods of managing tumor flare in adoptive immunotherapy

    Atara Biotherapeutics, Inc. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11918686

    Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents

    The Regents of the University of California · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11918660

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11912758

    Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel

    The Board of Regents of the University of Texas System · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11911367

    Methods for treating cancer

    Regents of the University of Minnesota · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11905268

    Anthranilic acid derivatives and their use in the treatment of human cancers

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11896558

    Use of an RXR agonist and taxanes in treating Her2+ cancers

    The Board of Regents of the University of Texas System · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11891402

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11891399

    Inhibitors of cancer invasion, attachment, and/or metastasis

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11883468

    Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11883420

    Sting agonists for treating bladder cancer and solid tumors

    VENENUM BIODESIGN, LLC · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11883492

    Combination treatment of chemoresistant cancers

    The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11879017

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11878961

    Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11872092

    Methods for surgical guidance in breast cancer surgery and lymph node dissection using two or more implantation devices comprising a capsule and a population of ultrasound-switchable fluorophores incorporated in the capsule

    The Board of Regents of the University of Texas System · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11865140

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11865157

    Compositions and methods of targeting cancer stem cells

    The Board of Regents of the University of Texas System · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11857573

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11858970

    Chili pepper seed isolated oligopeptide FTLE and application thereof in preventing or treating cancer

    China Agricultural University · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11857535

    Methods of treating mutant lymphomas

    Kymera Therapeutics, Inc. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11851711

    DNA methylation biomarkers for cancer diagnosing

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11851497

    CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

    Compass Therapeutics LLC · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11844799

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11844769

    Use of cysteamine and derivatives thereof to suppress tumor metastases

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11840525

    Use of AURKB small-molecule inhibitors for treatment of non-small cell lung cancer

    NANJING CHINA-AUSTRALIA INSTITUTE OF TRANSLATIONAL MEDICINE CO., LTD. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11834507

    Anti-MET agonist antibody for use in the treatment of colorectal cancer

    AGOMAB THERAPEUTICS · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11834499

    Claudin18 antibodies and methods of treating cancer

    The Regents of the University of California · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11826386

    Compositions and methods for treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11819517

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Iovance Biotherapeutics, Inc. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11814440

    Glypican 2 as a cancer marker and therapeutic target

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11807661

    Antibody fusion protein and related compositions for targeting cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11807853

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11806406

    Virus-like particle conjugates for diagnosis and treatment of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11801288

    Cancer vaccines and methods of treatment using the same

    Inovio Pharmaceuticals, Inc. · Granted Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11801265

    Preparation method of NK cells and use thereof in the treatment of cancer

    SINO UNITED (BEIJING) BIOMEDICAL TECHNOLOGY CO., LTD. · Granted Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11793816

    Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B

    Northwestern University · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11793772

    Pharmaceutical composition comprising THA as active ingredient for treating breast cancer

    KOREA UNITED PHARM. INC. · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11793810

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11786542

    Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways

    Northwestern University · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.